Online inquiry

IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12473MR)

This product GTTS-WQ12473MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL20 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001385165.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50604
UniProt ID Q9NYY1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12473MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2464MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ12429MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ1644MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ11020MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ5769MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ5486MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ14586MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ9773MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW